Post-earnings recap
Reported
Tue, Nov 5, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Xenon Pharmaceuticals' Q3 2019 results showed a loss per share of $0.33, but the stock still rose by 1.44%. The increase may reflect investor optimism about the company's ongoing clinical programs despite the lack of revenue and guidance. Overall, the market seems to be responding positively to their strategic direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.33 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management emphasized their commitment to ongoing clinical development. However, they did not offer any forward guidance during the call.
Management did not provide specific guidance for future quarters.
The focus remains on advancing their clinical programs.